Heart Disease or Cancer: Which is More Deadlier for Patients with Hodgkin Lymphoma?

Heart disease is the most common non-malignant long-term complication that patients with Hodgkin lymphoma (HL) patients suffer from.

People with early-stage Hodgkin lymphoma are at a higher risk of dying from heart disease than from cancer, reveals a new study.

Treatment advances have improved the survival of individuals with Hodgkin lymphoma (HL)—a type of cancer that affects the lymphatic system—but therapies can increase patients’ risk of developing heart problems.

Follicular Lymphoma - Causes, Symptoms, Diagnosis, Treatment and Prevention
Follicular lymphoma is a slow growing cancer of the lymph nodes. It is the most common form of slow growing B-cell non-Hodgkin’s lymphoma.

‘More effective measures are needed to reduce the risk and safeguard survivors’ heart health.’

A recent study published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society, reveals that people with early-stage HL are now at higher risk of dying from cardiovascular disease than from cancer.

Details of the Study

The multicenter study included 15,889 children and adults in the United States who were diagnosed with HL between 1983 and 2015. “We conducted this study because cardiovascular disease may be the most common non-malignant long-term complication and a prevalent cause for non-malignant death following treatment in HL survivors,” said senior author Caiwen Ou, MD, PhD, of Southern Medical University in Guangzhou, China.

Prof. Ou and colleagues found that among patients with stage I and stage II classic HL, the proportion of deaths from cardiovascular disease exceeded the proportion of deaths from classic HL after approximately 60 and 120 months of follow-up, respectively. Also, the cumulative incidence of cardiovascular disease mortality exceeded that of HL and other cancers over time.

In recent decades, the risk of mortality from classic HL declined sharply, but the risk of cardiovascular disease mortality among patients with classic HL declined slowly or even remained unchanged among some groups.

First-line Treatment of Stage III or IV Classical Hodgkin Lymphoma Approved
USFDA has approved an antibody-drug conjugate (Adcetris) in combination with chemotherapy as first-line treatment for stage III or IV classical Hodgkin lymphoma.

The analysis also revealed that patients with stage I or stage II classic HL experienced a higher risk of cardiovascular disease mortality than the general population at almost all follow-up intervals.

“Our results indicate that more effective measures are needed to reduce the risk of cardiovascular disease-related deaths in classic HL survivors,” said co-author Weijing Feng, MD, PhD.

New Treatment Target for Aggressive Non-Hodgkin Lymphomas Identified
MicroRNA miR-28 plays an important role by regulating the terminal differentiation of B lymphocytes and blocking their growth.

Source-Eurekalert

New Drug Used to Treat Hodgkin Lymphoma Shows Hope
A study shows that an FDA-approved drug increased the survival rate of patients with Hodgkins lymphoma by 200% without any progression of the disease.